Edition:
United States

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

5.25USD
21 Feb 2018
Change (% chg)

$0.10 (+1.94%)
Prev Close
$5.15
Open
$5.25
Day's High
$5.30
Day's Low
$5.25
Volume
1,980
Avg. Vol
9,773
52-wk High
$8.55
52-wk Low
$3.75

Chart for

About

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes... (more)

Overall

No Ratios Available.

Financials

  Industry Sector
P/E (TTM): -- 32.23 16.73
EPS (TTM): -- -- --
ROI: -- 14.02 35.60
ROE: -- 15.49 17.23

BRIEF-Kamada Ltd Q4 Earnings Per Share $0.16

* KAMADA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL-YEAR 2017

Feb 07 2018

BRIEF-Kamada Announces Data From Phase 2 Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment For Prevention Of Lung Transplant Rejection

* KAMADA ANNOUNCES INTERIM RESULTS FROM PHASE 2 CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION

Jan 08 2018

BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease

* KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE

Jan 04 2018

BRIEF-Kamada announces new supply agreement with international organization for KamRAB

* Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection

Nov 21 2017

BRIEF-Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy

* Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy

Nov 20 2017

BRIEF-Kamada announces CFO transition

* Kamada Ltd - Gil Efron, (deputy CEO) & Chief Financial Officer (CFO), recently informed company of his plan to leave at end of year

Sep 18 2017

BRIEF-Brosh Capital's Amir Efrati reports 6.2 pct stake in Kamada Ltd

* Brosh Capital Partners LP's Amir Efrati reports 6.2 Pct stake in Kamada Ltd as of Sept 1 - SEC filing Source text: (http://bit.ly/2h49AAz) Further company coverage:

Sep 13 2017

Earnings vs. Estimates